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Photodynamic therapy (PDT) in combination with chemo-
therapy has great potential for cancer treatment [1, 2]. However,
there have been very few attempts to develop cancer-targeted
co-delivery systems of photosensitizers and anticancer drugs.
We developed hematoporphyrin (HP)-modified doxorubicin
(DOX)-loaded bovine serum albumin nanoparticles (HP-NPs) in
an attempt to improve the therapeutic effect of PDT in treat-
ing liver cancer.
The HP-NPs were prepared by conjugation of amino groups
on the surface of nanoparticles with HP, which is not only a
ligand for low density lipoprotein (LDL) receptors on the
hepatoma cells but also a well-known photosensitizer for
PDT. In vitro phototoxicity in HepG2 (human hepatocellular
carcinoma) cells and in vivo anticancer efficacy in HepG2
tumor-bearing mice of free HP and HP-NPs were evaluated.
The laser conditions were fixed at 630 nm and 400 mW,
while the irradiation time and the number of PDT sessions
were variable.
The in vitro phototoxicity in HepG2 cells determined by MTT
assay, annexin V-FITC staining and FACS analysis was en-
hanced in HP-NPs compared with free HP. Furthermore,
compared with free HP-based PDT, in vivo anticancer efficacy
in HepG2 tumor-bearing mice was markedly improved by HP-
NPs-based PDT. Moreover, in both cases, the therapeutic effect
was increased according to the irradiation time and the number
of PDT sessions.
In conclusion, the HP-NPs prepared in this study repre-
sent a potentially effective co-delivery system of photosensitizer
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(HP) and anticancer drug (DOX), which improved the effects
of PDT in liver cancer.
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Fig. 1 – H&E staining of tumor tissues in HepG2 tumor-bearing mice on days 7 and 14, after double (on days 0 and 7)
intravenous injection of PBS, free HP and HP-NPs with 200 J/cm2 light irradiation 1 day after each injection (on days 1
and 8).
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